Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Invesco DB Commodity Index Tracking Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $282.7 (market cap $39.89B), while Invesco DB Commodity Index Tracking Fund trades at $27.81. The key difference: Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DBC | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $31.69 |
52-Week Low | $278.09 | $21.62 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DBC trades at $27.52, down slightly by 0.22% today, with technical indicators showing a bullish trend supported by moving averages. The commodity ETF recently hit a 52-week high in April 2026, driven by oil supply shocks and safe-haven demand. Recent news highlights commodities as effective inflation hedges, with DBC gaining over 32% in the past year.
The outlook remains positive given strong momentum and institutional interest in commodities for portfolio diversification. Key risks include geopolitical tensions affecting oil supplies and potential market volatility from inflation dynamics. Analyst sentiment is constructive, with DBC positioned to benefit from ongoing commodity strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
